BN Business News
Add your company to Business Communicator →

Business · 16/11/20261 min read

Protego Presents New Data at ISA 2026 that Advances Evidence for Light-Chain Stabilization with PROT-001 in AL Amyloidosis

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

- PROT-001, the company's investigational oral small molecule drug for AL amyloidosis, demonstrated an acceptable safety and tolerability profile in a healthy volunteer Phase 1 study - In human cardiomyocyte and plasma cell studies, PROT-001 reduced markers of stress and toxicity, and...

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →